Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker.

Anand JoshiJianxia GuoJulianne L HolleranBrian KieselSarah TaylorSusan ChristnerRobert A PariseBrian M MillerS Percy IvyEdward ChuRaman VenkataramananJan H Beumer

Published in: Cancer chemotherapy and pharmacology (2020)

Iohexol is unlikely to affect the clinical pharmacokinetics of carboplatin, paclitaxel, gemcitabine, or other agents used in combination with carboplatin treatment. Measuring GFR with iohexol to better dose carboplatin is unlikely to alter the safety or efficacy of chemotherapy through pharmacokinetic drug-drug interactions.

Keyphrases

phase ii study
locally advanced
phase iii
drug induced
radiation therapy